Business Wire

NY-ANTIDOTE-TECHNOLOGIES

14.4.2020 15:02:11 CEST | Business Wire | Press release

Share
Antidote Technologies Unveils Smart COVID-19 Clinical Trial Search to Speed Up Treatment and Vaccine Research Worldwide

Antidote Technologies, a digital patient engagement company with strategic partnerships across the clinical development ecosystem, today announced the addition of COVID-19 trials to its signature state-of-the-art clinical trial search platform, Antidote Match™. For the first time, people can use Antidote’s search to be quickly matched to clinical trials for compounds aimed at COVID-19 treatment and prevention.

Antidote Match is the first trial matching engine that uses structured eligibility criteria (using industry standard and custom-designed ontologies) and proprietary algorithms to explore a patient’s eligibility for every trial. When searching COVID-19 trials, patients answer a handful of questions about their health, and the Antidote Match engine traverses all COVID-19 trials in ClinicalTrials.gov, regardless of location, to connect them with the right studies.

Antidote’s search is available on the Antidote website and on the websites of 250+ patient advocacy groups, where Antidote powers clinical trial search. “Antidote is a tremendous resource for families looking for clear, reliable information on clinical trials, as well as scientists hoping to accelerate the path to new and more effective treatments,” said Michael Buckley, Vice President of Public Affairs at BrightFocus Foundation.

Traditionally, medical research has been a slow process — it takes an average of ten years for a drug to go from initial discovery to pharmacy shelves.1 “Right now, the world doesn’t have ten years,” said Laurent Schockmel, CEO of Antidote. “COVID-19 research is urgent, and all avenues that speed up research should be explored. That’s why Antidote is providing this free search tool to all. It’s simple: the more patients search and enroll, the faster medical research can lead to breakthroughs to treat and prevent COVID-19.”

Clinical trials for COVID-19 cannot move forward without volunteers — both those who are sick and those who are healthy. To be part of finding a solution to COVID-19, please visit http://www.antidote.me/covid-19 .

About Antidote

Antidote is a digital health company on a mission to accelerate medical research. In a world where eighty percent of clinical trials are delayed or closed due to lack of participants, Antidote uses precision recruitment to match the right patients with the right trials.2 Antidote strikes the right balance between technology and human touch to deliver high-quality patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit www.antidote.me .

References

  1. PhRMA. (2015). Biopharmaceutical Research & Development: The Process Behind New Medicines [whitepaper]. http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf .
  2. Hargreaves, B. (2016, March). Clinical Trials and their Patients: The Rising Costs and How to Stem the Loss. Pharmafile. http://www.pharmafile.com/news/511225/clinical-trials-and-their-patients-rising-costs-and-how-stem-loss .

Link:

ClickThru

Social Media:

https://www.facebook.com/antidote.me

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release

Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 15:17:00 CET | Press release

Collaboration brings together Argenta's Molecule to Market capabilities and Loyal’s lifespan extension therapeutics with early development of LOY-003 Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candida

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 15:08:00 CET | Press release

From the next evolution of Nike Air to new Nike Mind and Nike Free footwear, Nike is solving distinct athlete needs — and creating platforms that can bring those breakthroughs to more athletes.New innovations and platforms span running, training, basketball, football and outdoor sports, reflecting Nike's focus on delivering best-in-class performance to athletes across disciplines.Nike is bringing performance innovation into everyday style, reinventing the classics athletes love while introducing new silhouettes, including Project Ride and Nike Morpho X.Much of what Nike is showing arrives over the coming year, with some innovations following later. Watch for more details in the months to come. NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com

2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release

The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye